Johnson & Johnson is a company operating in consumer, pharmaceutical and medical device categories. Johnson & Johnson is engaged in research and development, manufacture and sale of healthcare products. The consumer segment includes baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care. The pharmaceutical segment includes immunology, infectious disease, neuroscience, oncology, cardiovascular disease and metabolic disease. Their medical device segment includes orthopedic, surgery, cardiovascular, diabetes care and vision care. J&J has research facilities in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.
Johnson & Johnson teamed up with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop a vaccine against the new coronavirus strain responsible for the COVID-19 outbreak. J&J will use its AdVac viral vector and PER.C6 cell line for coronavirus vaccine development. These are the same technologies used to develop an Ebola vaccine that is in testing in Africa, prophylactics against Zika, HIV and respiratory syncytial virus. J&J’s Janssen unit and BARDA plan to co-fund research and development of the vaccine and make their resources available. J&J donated bottles of its HIV drug darunavir/cobicistat, marketed under the brand name Prezcobix, to researchers in China investigating it as a potential treatment for the new coronavirus. Other J&J antiviral drugs on the market or in its pipeline will be included in research to test if they could help the fight the novel coronavirus strain causing the COVID-19 outbreak.
J&J allies with BARDA to accelerate coronavirus vaccine program
Johnson & Johnson acquires Auris Health.
Johnson & Johnson announced that its Ethicon biz completed $3.4 billion acquisition of robotic surgery dev Auris Health.
Joseph A Bianco III
Kim Michael Janas, MBA
Mohamed El Beltagi
Sushil Pratap Bharati